Porcine parvovirus (PPV) and leptospirosis represent significant threats to pig health and swine farms, leading to substantial losses related to sow infertility, abortions, and the birth of stillborn or mummified piglets. Furthermore, while leptospirosis is rare in humans, it poses a risk to breeders in contact with infected animals due to its transmissibility.

Evolving epidemiological and vaccination landscape

While PPV is globally endemic, leptospirosis, though more frequent in tropical regions, is experiencing an increasing incidence in France. Faced with these pathologies historically managed by antibiotherapy, vaccination is an increasingly favored preventive approach by veterinarians in the context of combating antibiotic resistance. The complexity of leptospirosis diagnosis further reinforces the value of prevention. Moreover, the resurgence of parvovirosis cases from 2022 among vaccinated sows questioned the efficacy of existing vaccines against circulating strains.

A new vaccine adapted to on-the-ground realities

We are now offering a combined vaccine in France against leptospirosis and porcine parvovirus, targeting the prevalent strains in the territory. This solution aims to reduce viral circulation, prevent transplacental transmission and fetal mortality due to parvovirus, and prevent transplacental transmission as well as clinical signs associated with leptospirosis, particularly the Australis and Icterohaemorrhagiae serovars.

At Virbac, we are committed to supporting swine veterinarians and breeders with prevention-focused solutions. Since 2023, we have launched three new porcine vaccines in France and Germany to address these challenges. The introduction of a fourth vaccine, specifically dedicated to the French market, reaffirms our commitment. We develop solutions that integrate local epidemiological specificities to precisely meet the needs of breeders and veterinarians worldwide.